Basit öğe kaydını göster

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

dc.contributor.authorDe Giorgi, Ugo
dc.contributor.authorGalsky, Matthew D.
dc.contributor.authorArranz Arija, Jose Angel
dc.contributor.authorBamias, Aristotelis
dc.contributor.authorDavis, Ian D.
dc.contributor.authorDe Santis, Maria
dc.contributor.authorKikuchi, Eiji
dc.contributor.authorGarcia-del-Muro, Xavier
dc.contributor.authorMencinger, Marina
dc.contributor.authorIzumi, Kouji
dc.contributor.authorPanni, Stefano
dc.contributor.authorGÜMÜŞ, MAHMUT
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorKalebasty, Arash Rezazadeh
dc.contributor.authorPark, Se Hoon
dc.contributor.authorAlekseev, Boris
dc.contributor.authorSchutz, Fabio A.
dc.contributor.authorLi, Jian-Ri
dc.contributor.authorYe, Dingwei
dc.contributor.authorVogelzang, Nicholas J.
dc.contributor.authorBernhard, Sandrine
dc.contributor.authorTayama, Darren
dc.contributor.authorMariathasan, Sanjeev
dc.contributor.authorMecke, Almut
dc.contributor.authorThastrom, AnnChristine
dc.contributor.authorGrande, Enrique
dc.date.accessioned2021-03-02T18:30:59Z
dc.date.available2021-03-02T18:30:59Z
dc.date.issued2020
dc.identifier.citationGalsky M. D. , Arranz Arija J. A. , Bamias A., Davis I. D. , De Santis M., Kikuchi E., Garcia-del-Muro X., De Giorgi U., Mencinger M., Izumi K., et al., "Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial", LANCET, cilt.395, ss.1547-1557, 2020
dc.identifier.issn0140-6736
dc.identifier.otherav_d7ec5b72-1862-42e7-bbb6-0045e233e5c1
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/5056
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(20)30230-0
dc.description.abstractBackground Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectTemel Tıp Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectTIP, GENEL & İÇECEK
dc.subjectTıp
dc.titleAtezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.departmentIcahn School Of Medicine At Mount Sinai , ,
dc.identifier.volume395
dc.identifier.issue10236
dc.identifier.startpage1547
dc.identifier.endpage1557
dc.contributor.firstauthorID2281730


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster